- A bipartisan coalition of 50 states, D.C., and two territories reached settlements with Heritage Pharmaceuticals, Inc. and Apotex Corp. to resolve allegations of price fixing generic drugs in violation of the Sherman Act.
- As part of complaints filed in 2017 and 2019, the AGs allege that the companies, along with other drug manufacturers and their executives, coordinated to inflate prices for multiple generic drugs used to treat a number of conditions, among other things.
- Under the terms of the settlement agreement with Heritage, the company is required to pay $10 million to be used for restitution and costs. According to the AGs, Apotex is required to pay $39 million. Both companies must also cooperate in ongoing litigation against other companies.
- We have previously reported on Mississippi AG Lynn Finch's settlement with Teva Pharmaceuticals USA, Inc. to resolve similar claims.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
Find out more and explore further thought leadership around Food, Drugs, Healthcare, Life Sciences
